Cheryl A. Janson

Montclair State University — United States

Materials Science · Physical Sciences

50h-index7.4kcitations135works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Enzyme Structure and Function(24), Biochemical and Molecular Research(21), Protease and Inhibitor Mechanisms(12), Bone Metabolism and Diseases(11), RNA and protein synthesis mechanisms(9)

Publications135 total

Investigating the Roles of Active Site Residues in <i>Mycobacterium tuberculosis</i> Indole-3-glycerol Phosphate Synthase, a Potential Target for Antitubercular Agents
ACS Bio & Med Chem Au·2023· 1 citedOpen Access
Crystal structure of dihydrofolate reductase from the filarial nematode W. bancrofti in complex with NADPH and folate
PLoS neglected tropical diseases·2023· 3 citedOpen Access
Mutational analysis confirms the presence of distal inhibitor-selectivity determining residues in B. stearothermophilus dihydrofolate reductase
Archives of Biochemistry and Biophysics·2020Open Access
CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 12-(6-tert-butyl-8-fluoro-1-oxo-phthalazin-2-yl)-9-hydroxy-6-methyl-4-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-azatricyclo[9.4.0.02,7]pentadeca-1(15),2(7),3,11,13-pentaen-5-one
2018
Expression, purification, and inhibition profile of dihydrofolate reductase from the filarial nematode Wuchereria bancrofti
PLoS ONE·2018· 15 citedOpen Access
Crystallization and Study of Dihydrofolate Reductases (DHFR) in <i>Wuchereria bancrofti</i> and <i>Brugia malayi</i> .
The FASEB Journal·2018
Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors
ACS Medicinal Chemistry Letters·2015· 21 citedOpen Access
CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR
2015
Crystal structure of BTK kinase domain complexed with 6-(dimethylamino)-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(morpholine-4-carbonyl)-2-pyridyl]amino]-6-oxo-3-pyridyl]phenyl]-3,4-dihydroisoquinolin-1-one
2014
Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Bioorganic & Medicinal Chemistry·2014· 55 cited
Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors
Bioorganic & Medicinal Chemistry Letters·2013· 54 citedOpen Access
The 1.7A Crystal Structure of MDMX with a Stapled Peptide, ATSP-7041
2013
Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain
Journal of Medicinal Chemistry·2013· 38 citedOpen Access
human FGFR1 kinase in complex with CH5183284
2013
Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain
Journal of Medicinal Chemistry·2013· 28 citedOpen Access
The crystal structure of DYRK1a with a bound pyrido[2,3-d]pyrimidine inhibitor
2013
The structure of XIAP BIR2: understanding the selectivity of the BIR domains
Acta Crystallographica Section D Biological Crystallography·2013· 39 citedOpen Access
The 2.3A Crystal Structure of Humanized Xenopus MDM2 with RO5545353
2013
The 1.14A Crystal Structure of Humanized Xenopus MDM2 with RO5499252
2013
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Journal of Medicinal Chemistry·2013· 583 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Ward W. Smith(22), Xiayang Qiu(15), Sherin S. Abdel‐Meguid(12), Thaddeus A. Tomaszek(9), Daniel F. Veber(9), Michael S. McQueney(9), Baoguang Zhao(9), David Payne(8), Martha S. Head(8), Karla D'Alessio(7), Robert J. Almassy(6), Walter E. DeWolf(6), Stephen Rittenhouse(6), David Eisenberg(5), S. Pearson(5), Mark A. Levy(5), Paul M. Keller(5), David G. Tew(5), Scott K. Thompson(5), William H. Miller(5)